To further investigate the potential dependency of prostate carcinoma on NKX3.1, we performed a competition assay using independent sgRNAs targeting NKX3.1 and confirmed that NKX3.1 loss significantly reduced the viability of LNCaP_FGC and other LNCaP strains to a level that approximated the effects of AR deletion (Figure 9, D–H). Here, AR is linked to prostate carcinoma.